Muneer G. Hasham received his A.B. from Bowdoin College and his Ph.D. from Temple University School of Medicine in Microbiology and Immunology. His thesis was on cancer virology. He joined The Jackson Laboratory as a post-doctoral fellow in 2003 using mouse models to find novel cures for various types of cancer, autoimmune and cardiac diseases. He remained as a post-doctoral fellow and then as a Research Scientist until 2021 when he became a Study Director, and then in 2023, an Associate Director for XLIS. He provides study design and regulatory expertise for pre-clinical and in vivo cell line and patient-derived xenograft cancer growth, chemotherapy and immunotherapy efficacy studies, and live imaging systems. He has decades of expertise in cellular assays and tissue culture propagation of cancer cell lines. In addition, Hasham has taught cancer genetics, courses on mouse models for cancer research and/or imaging systems for more than a decade via JAX Education. In his independent research, Hasham is focused on understanding the contribution of micro-environment genetics on cancer growth and response to chemotherapy, immunotherapy and novel drug delivery systems.
Excellence and innovation are the values exemplified in our services. The staff of XLIS have several patents and have assisted in preclinical studies leading to human clinical trials.
For example, we recently innovated xenograft studies by demonstrating the importance of using multiple host strains. The XLIS team currently includes the Associate Director who oversees the service, a Supervisor who takes care of daily mouse room and imaging activities, and a team of Xenograft Study Technicians. We work closely together as a team to ensure the best service is provided to JAX investigators. As we expand, be on the lookout for a job posting!
Loading...